REFERENCES
1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer 2015;136:E359-86.
2. Ministery of Health. Bolivarian Republic of Venezuela. Anuary of Mortality 2013. Available from: http://www.ovsalud.org/descargas/publicaciones/documentos-oficiales/Anuario-Mortalidad-2013.pdf [Last accessed on 19 Jan 2018].
3. Hainaut P, Plymoth A. Targeting the hallmarks of cancer: towards a rational approach to next-generation cancer therapy. Curr Opin Oncol 2013;25:50-1.
4. Burrell R, McGranahan N, Bartek J, Swanton C. The causes and consequences of genetic heterogeneity in cancer evolution. Nature 2013;501:338-45.
5. Fisher R, Pusztai L, Swanton C. Cancer heterogeneity: implications for targeted therapeutics. Br J Cancer 2013;108:479-85.
6. Spratt D, Pei X, Yamada J, Kollmeier M, Cox B, Zelefsky M. Long-term survival and toxicity in patients treated with high-dose intensity modulated radiation therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2013;85:686-92.
7. Senn H. Gallen consensus 2013: optimizing and personalizing primary curative therapy of breast cancer worldwide. Breast Care 2013;8:101.
8. Khawar I, Kim J, Kuh H. Improving drug delivery to solid tumors: Priming the tumor microenvironment. J Control Release 2015;201:78-89.
9. Nagarsheth N, Wicha M, Zou W. Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy. Nat Rev Immunol 2017;17:559-72.
10. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob J, Cowey C, Lao C, Schadendorf D, Dummer R, Smylie M, Rutkowski P, Ferrucci PF, Hill A, Wagstaff J, Carlino MS, Haanen JB, Maio M, Marquez-Rodas I, McArthur GA, Ascierto PA, Long GV, Callahan MK, Postow MA, Grossmann K, Sznol M, Dreno B, Bastholt L, Yang A, Rollin LM, Horak C, Hodi FS, Wolchok JD. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015;373:23-34.
11. Wolchok J, Chiarion-Sileni V, Gonzalez R, Rutkowski P, Grob J, Cowey C, Lao C, Wagstaff J, Schadendorf D, Ferrucci P, Smylie M, Dummer R, Hill A, Hogg D, Haanen J, Carlino M, Bechter O, Maio M, Marquez-Rodas I, Guidoboni M, McArthur G, Lebbé C, Ascierto P, Long G, Cebon J, Sosman J, Postow M, Callahan M, Walker D, Rollin L, Bhore R, Hodi F, Larkin J. Overall survival with combined Nivolumab and Ipilimumab in advanced melanoma. N Engl J Med 2017;377:345-56.
12. Babjuk M, Böhle A, Burger M, Capoun O, Cohen D, Compérat E, Hernández V, Kaasinen E, Palou J, Rouprêt M, van Rhijn BWG, Shariat SF, Soukup V, Sylvester RJ, Zigeuner R. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol 2017;71:447-61.
13. Roberts N, Zhang L, Janku F, Collins A, Bai R, Staedtke V, Rusk AW, Tung D, Miller M, Roix J, Khanna KV, Murthy R, Benjamin RS, Helgason T, Szvalb AD, Bird JE, Roy-Chowdhuri S, Zhang HH, Qiao Y, Karim B, McDaniel J, Elpiner A, Sahora A, Lachowicz J, Phillips B, Turner A, Klein MK, Post G, Diaz LA Jr, Riggins GJ, Papadopoulos N, Kinzler KW, Vogelstein B, Bettegowda C, Huso DL, Varterasian M, Saha S, Zhou S. Intratumoral injection of Clostridium novyi-NT spores induces antitumor responses. Sci Transl Med 2014;6:249ra111.
14. Toneri M, Miwa S, Zhang Y, Hu C, Yano S, Matsumoto Y, Bouvet M, Nakanishi H, Hoffman RM, Zhao M. Tumor-targeting Salmonella typhimurium A1-R inhibits human prostate cáncer experimental bone metástasis in mouse models. Oncotarget 2015;6:31335-43.
15. Laurence M, Yvonne P. Attenuated listeria monocytogenes: a powerful and versatile vector for the future of tumor immunotherapy. Front Cell Infect Microbiol 2014;4:51.
16. Gatenby R, Brown J. Mutations, evolution and the central role of a self-defined fitness function in the initiation and progression of cancer. Biochim Biophys Acta 2017;1867:162-6.
17. Zheng S, Widschwendter M, Teschendorff A. Epigenetic drift, epigenetic clocks and cancer risk. Epigenomics 2016;8:705-19.
18. Grasso Frisan T. Bacterial genotoxins: merging the DNA damage response into infection biology. Biomolecules 2015;5:1762-82.
20. Behrens A, van Deursen J, Rudolph K, Schumacher B. Impact of genomic damage and ageing on stem cell function. Nat Cell Biol 2014;16:201-7.
21. Charni M, Aloni-Grinstein R, Molchadsky A, Rotter V. p53 on the crossroad between regeneration and cancer. Cell Death Differ 2016;24:8-14.
22. Xu JH, Hu SL, Shen GD, Shen G. Tumor suppressor genesand their underlying interactions in paclitaxel resistance in cancer therapy. Cancer Cell Int 2016;16:13.
23. Shalapour S, Karin M. Immunity, inflammation, and cancer: an eternal fight between good and evil. J Clin Invest 2015;125:3347-55.
24. Garg A, Dudek A, Agostinis P. Cancer immunogenicity, danger signals, and DAMPs: what, when, and how? Biofactors 2013;39:355-67.
25. Pritchard A, Hastie M, Neller M, Gorman J, Schmidt C, Hayward N. Exploration of peptides bound to MHC class I molecules in melanoma. Pigment Cell Melanoma Res 2015;28:281-94.
26. Galon J, Angell H, Bedognetti D, Marincola F. The continuum of cancer immunosurveillance: prognostic, predictive, and mechanistic signatures. Immunity 2013;39:11-26.
27. Romee R, Leong J, Fehniger T. Utilizing cytokines to function-enable human NK cells for the immunotherapy of cancer. Scientifica (Cairo) 2014;2014:205796.
28. Gajewski T, Schreiber H, Fu Y. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 2013;14:1014-22.
29. Payne K, Bear H, Manjili M. Adoptive cellular therapy of cancer: exploring innate and adaptive cellular crosstalk to improve anti-tumor efficacy. Future Oncol 2014;10:1779-94.
30. Gajewski TF, Schreiber H, Fu YX. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol 2013;14:1014-22.
31. Jandus C, Boligan K, Chijioke O, Liu H, Dahlhaus M, Démoulins T, Schneider C, Wehrli M, Hunger RE, Baerlocher GM, Simon HU, Romero P, Münz C, von Gunten S. Interactions between Siglec-7/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance. J Clin Invest 2014;124:1810-20.
32. Morvan M, Lanier L. NK cells and cancer: you can teach innate cells new tricks. Nat Rev Cancer 2015;16:7-19.
33. Crouse J, Xu H, Lang P, Oxenius A. NK cells regulating T cell responses: mechanisms and outcome. Trends Immunol 2015;36:49-58.
34. D'Eliseo D, Manzi L, Velotti F. Capsaicin as an inducer of damage-associated molecular patterns (DAMPs) of immunogenic cell death (ICD) in human bladder cancer cells. Cell Stress Chaperones 2013;18:801-8.
35. Deauvieau F, Ollion V, Doffin A, Achard C, Fonteneau J, Verronese E, Durand I, Ghittoni R, Marvel J, Dezutter-Dambuyant C, Walzer T, Vie H, Perrot I, Goutagny N, Caux C, Valladeau-Guilemond J. Human natural killer cells promote cross-presentation of tumor cell-derived antigens by dendritic cells. Int J Cancer 2014;136:1085-94.
36. Ferlazzo G, Moretta L. Dendritic cell editing by natural killer cells. Crit Rev Oncog 2014;19:67-75.
37. Messina J, Fenstermacher D, Eschrich S, Qu X, Berglund A, Lloyd M, Schell MJ, Sondak VK, Weber JS, Mulé JJ. 12-Chemokine gene signature identifies lymph node-like structures in melanoma: potential for patient selection for immunotherapy? Sci Rep 2012;2:765.
38. Wilk E, Kalippke K, Buyny S, Schmidt R, Jacobs R. New aspects of NK cell subset identification and inference of NK cells' regulatory capacity by assessing functional and genomic profiles. Immunobiology 2008;213:271-83.
39. Della Chiesa M, Marcenaro E, Sivori S, Carlomagno S, Pesce S, Moretta A. Human NK cell response to pathogens. Semin Immunol 2014;26:152-60.
40. Slezak S, Worschech A, Wang E, Stroncek D, Marincola F. Analysis of vaccine-induced T cells in humans with cancer. Adv Exp Med Biol 2010;684:178-88.
41. Bhatia A, Kumar Y. Cancer stem cells and tumor immunoediting: putting two and two together. Expert Rev Clin Immunol 2016;12:605-7.
42. Calì B, Molon B, Viola A. Tuning cancer fate: the unremitting role of host immunity. Open Biol 2017;7:170006.
43. Mittal D, Gubin M, Schreiber R, Smyth M. New insights into cancer immunoediting and its three component phases-elimination, equilibrium and escape. Curr Opin Immunol 2014;27:16-25.
44. Wu X, Peng M, Huang B, Zhang H, Wang H, Huang B, Xue Z, Zhang L, Da Y, Yang D, Yao Z, Zhang R. Immune microenvironment profiles of tumor immune equilibrium and immune escape states of mouse sarcoma. Cancer Lett 2013;340:124-33.
45. Teng M, Galon J, Fridman W, Smyth M. From mice to humans: developments in cancer immunoediting. J Clin Invest 2015;125:3338-46.
46. Spranger S, Koblish H, Horton B, Scherle P, Newton R, Gajewski T. Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8+ T cells directly within the tumor microenvironment. J Immunother Cancer 2014;2:3.
47. Postow M, Callahan M, Wolchok J. Immune checkpoint blockade in cancer therapy. J Clin Oncol 2015;33:1974-82.
48. Vesely M, Schreiber R. Cancer immunoediting: antigens, mechanisms, and implications to cancer immunotherapy. Ann N Y Acad Sci 2013;1284:1-5.
49. Sakamoto C, Kohara H, Inoue H, Narusawa M, Ogawa Y, Hirose-Yotsuya L, Miyamoto S, Matsumura Y, Yamada K, Takahashi A, Tani K. Therapeutic vaccination based on side population cells transduced by the granulocyte-macrophage colony-stimulating factor gene elicits potent antitumor immunity. Cancer Gene Ther 2017;24:165-74.
51. Vedham V, Divi R, Starks V, Verma M. Multiple infections and cancer: implications in epidemiology. Technol Cancer Res Treat 2014;13:177-94.
52. Khan S, Imran A, Khan A, AbulKalam M, Alshamsan A. Systems biology approaches for the prediction of possible role of chlamydia pneumoniae proteins in the etiology of lung cancer. PLoS One 2016;11:e0148530.
53. Crowe S. Helicobacter infection, chronic inflammation, and the development of malignancy. Curr Opin Gastroenterol 2005;21:32-8.
54. Krishnan S, Eslick G. Streptococcus bovisinfection and colorectal neoplasia: a meta-analysis. Colorectal Dis 2014;16:672-80.
55. Hardbower D, de Sablet T, Chaturvedi R, Wilson K. Chronic inflammation and oxidative stress. Gut Microbes 2013;4:475-81.
56. Manda G, Isvoranu G, Comanescu M, Manea A, Debelec Butuner B, Korkmaz K. The redox biology network in cancer pathophysiology and therapeutics. Redox Biol 2015;5:347-57.
57. Kidane D, Chae WJ, Czochor J, Eckert KA, Glazer PM, Bothwell AL, Sweasy JB. Interplay between DNA repair and inflammation, and the link to cancer. Crit Rev Biochem Mol Biol 2014;49:116-39.
58. Hoesel B, Schmid J. The complexity of NF-κB signaling in inflammation and cancer. Mol Cancer 2013;12:86.
59. Elinav E, Nowarski R, Thaiss C, Hu B, Jin C, Flavell R. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer 2013;13:759-71.
61. Van T, Polykratis A, Straub B, Kondylis V, Papadopoulou N, Pasparakis M. Kinase-independent functions of RIPK1 regulate hepatocyte survival and liver carcinogenesis. J Clin Invest 2017;127:2662-77.
62. Gambhir S, Vyas D, Hollis M, Aekka A, Vyas A. Nuclear factor kappa B role in inflammation associated gastrointestinal malignancies. World J Gastroenterol 2015;21:3174-83.
63. Pawlowski A, Jansson M, Sköld M, Rottenberg ME, Källenius G. Tuberculosis and HIV co-Infection. PLoS Pathog 2012;8:e1002464.
64. Scanu T, Spaapen R, Bakker J, Pratap C, Wu L, Hofland I, Broeks A, Shukla VK, Kumar M, Janssen H, Song JY, Neefjes-Borst EA, te Riele H, Holden DW, Nath G, Neefjes J. Salmonella manipulation of host signaling pathways provokes cellular transformation associated with gallbladder carcinoma. Cell Host Microbe 2015;17:763-74.
65. Zhang Y, Li S, Gan R, Zhou T, Xu D, Li H. Impacts of gut bacteria on human health and diseases. Int J Mol Sci 2015;16:7493-519.
66. Bernardes N, Chakrabarty A, Fialho A. Engineering of bacterial strains and their products for cancer therapy. Appl Microbiol Biotechnol 2013;97:5189-99.
67. Nauts H, Swift W, Coley B. The treatment of malignant tumors by bacterial toxins as developed by the late William B. Coley, MD, reviewed in the light of modern research. Cancer Res 1946;6:205-16.
68. Coley W. End results in Hodgkin's disease and lymphosarcoma treated by the mixed toxins of erysipelas and bacillus prodigiosus, alonis or combined with radiation. Ann Surg 1928;88:641.
69. Coley W. Treatment of inoperable malignant tumors with the toxines of erysipelas and the bacillus prodigiosus. Am J Med Sci 1894;108:50-66.
70. Coley W. The treatment of malignat tumors by repeated inoculations of erysipelas. Am J Med Sci 1893;105:487-510.
71. Coley W. The mixed toxins of erysipelas and bacillus prodigiosus in the treatment of sarcoma. JAMA 1900;XXXIV:906-8.
72. Nauts HC. The beneficial effects of bacterial infections on host resistance to cancer end results in 449 cases: a study and abstracts of reports in the world medical literature (1775-1980) and personal communications. Cancer Research Inst 1980;24:212-6.
73. Sell S. Cancer immunotherapy: breakthrough or "deja vu, all over again"? Tumor Biol 2017;39:1010428317707764.
74. Kienle G. Fever in cancer treatment: Coley's therapy and epidemiologic observations. Glob Adv Health Med 2012;1:92-100.
75. Rosenberg S. IL-2: the first effective immunotherapy for human cancer. J Immunol 2014;192:5451-8.
76. Le H, Lee N, Tsung K, Norton J. Pre-existing tumor-sensitized T cells are essential for eradication of established tumors by IL-12 and cyclophosphamide plus IL-12. J Immunol 2001;167:6765-72.
77. Kucerova P, Cervinkova M. Spontaneous regression of tumour and the role of microbial infection-possibilities for cancer treatment. Anticancer Drugs 2016;27:269-77.
78. Nallar S, Xu D, Kalvakolanu D. Bacteria and genetically modified bacteria as cancer therapeutics: current advances and challenges. Cytokine 2017;89:160-72.
79. Chorobik P, Czaplicki D, Ossysek K, Bereta J. Salmonella and cancer: from pathogens to therapeutics. Acta Biochim Pol 2013;60:285-97.
81. Brown K, Brown G, Lewis S, Beale R, Treacher D. Targeting cytokines as a treatment for patients with sepsis: a lost cause or a strategy still worthy of pursuit? Int Immunopharmacol 2016;36:291-9.
82. Dang LH, Bettegowda C, Huso DL, Kinzler KW, Vogelstein B. Combination bacteriolytic therapy for the treatment of experimental tumors. Proc Natl Acad Sci U S A 2001;98:15155-60.
83. Gujrati V, Kim S, Kim S, Min J, Choy H, Kim S, Jon S. Bioengineered bacterial outer membrane vesicles as cell-specific drug-delivery vehicles for cancer therapy. ACS Nano 2014;8:1525-37.
84. Piñero-Lambea C, Bodelón G, Fernández-Periáñez R, Cuesta A, Álvarez-Vallina L, Fernández L. Programming controlled adhesion of E. coli to target surfaces, cells, and tumors with synthetic adhesins. ACS Synth Biol 2015;4:463-73.
85. Lin I, Van T, Smooker P. Live-attenuated bacterial vectors: tools for vaccine and therapeutic agent delivery. Vaccines 2015;3:940-72.
86. Kasinskas R, Forbes N. Salmonella typhimurium lacking ribose chemoreceptors localize in tumor quiescence and induce apoptosis. Cancer Res 2007;67:3201-9.
87. Loeffler M, Le'Negrate G, Krajewska M, Reed J. Salmonella typhimurium engineered to produce CCL21 inhibit tumor growth. Cancer Immunol Immunother 2008;58:769-75.
88. Sahari A, Traore M, Scharf B, Behkam B. Directed transport of bacteria-based drug delivery vehicles: bacterial chemotaxis dominates particle shape. Biomed Microdevices 2014;16:717-25.
90. Alphandéry E. Applications of magnetosomes synthesized by magnetotactic bacteria in medicine. Front Bioeng Biotechnol 2014;2:5.
91. Pyne M, Bruder M, Moo-Young M, Chung D, Chou C. Technical guide for genetic advancement of underdeveloped and intractable Clostridium. Biotechnol Adv 2014;32:623-41.
92. Nallar S, Xu D, Kalvakolanu D. Bacteria and genetically modified bacteria as cancer therapeutics: current advances and challenges. Cytokine 2017;89:160-72.
93. Claesen J, Fischbach M. Synthetic microbes as drug delivery systems. ACS Synth Biol 2015;4:358-64.
94. Abil Z, Xiong X, Zhao H. Synthetic biology for therapeutic applications. Mol Pharm 2014;12:322-31.
95. Allen E, Miéville P, Warren CM, Saghafinia S, Li L, Peng MW, Hanahan D. Metabolic symbiosis enables adaptive resistance to anti-angiogenic therapy that is dependent on mTOR signaling. Cell Rep 2016;15:1144-60.
97. Phillips R. Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs. Cancer Chemother Pharmacol 2016;77:441-57.
98. Hunter F, Wouters B, Wilson W. Hypoxia-activated prodrugs: paths forward in the era of personalised medicine. Br J Cancer 2016;114:1071-7.
99. Rhim T, Lee D, Lee M. Hypoxia as a target for tissue specific gene therapy. J Control Release 2013;172:484-94.
100. Dhani N, Fyles A, Hedley D, Milosevic M. The clinical significance of hypoxia in human cancers. Semin Nucl Med 2015;45:110-21.
101. Heap J, Theys J, Ehsaan M, Kubiak A, Dubois L, Paesmans K, Van Mellaert L, Knox R, Kuehne SA, Lambin P, Minton NP. Spores of Clostridium engineered for clinical efficacy and safety cause regression and cure of tumors in vivo. Oncotarget 2014;5:1761-9.
102. Hammerich L, Brody JD. Immunomodulation within a single tumor site to induce systemic antitumor immunity: in situ vaccination for cancer. In: Rennert P, editor. Novel Immunotherapeutic Approaches to the Treatment of Cancer. Cham: Springer; 2016. pp. 129-62.
103. Park D, Park S, Cho S, Lee Y, Lee Y, Min J, Park BJ, Ko SY, Park JO, Park S. Motility analysis of bacteria-based microrobot (bacteriobot) using chemical gradient microchamber. Biotechnol Bioeng 2014;111:134-43.
104. Yu B, Shi L, Zhang BZ, Zhang KE, Peng X, Niu HB, Qu JL. Obligate anaerobic Salmonella typhimurium strain YB1 treatment on xenograft tumor in immunocompetent mouse model. Oncol Lett 2015;10:1069-74.
105. Thornlow D, Brackett E, Gigas J, Van Dessel N, Forbes N. Persistent enhancement of bacterial motility increases tumor penetration. Biotechnol Bioeng 2015;112:2397-405.
106. Pylaeva E, Lang S, Jablonska J. The essential role of type I interferons in differentiation and activation of tumor-associated neutrophils. Front Immunol 2016;7:629.
107. Hiroshima Y, Zhao M, Zhang Y, Zhang N, Maawy A, Murakami T, Mii S, Uehara F, Yamamoto M, Miwa S, Yano S, Momiyama M, Mori R, Matsuyama R, Chishima T, Tanaka K, Ichikawa Y, Bouvet M, Endo I, Hoffman RM. Tumor-targeting salmonella typhimurium A1-R arrests a chemo-resistant patient soft-tissue sarcoma in nude mice. PLoS One 2015;10:e0134324.
108. Matsumoto Y, Miwa S, Zhang Y, Hiroshima Y, Yano S, Uehara F, Yamamoto M, Toneri M, Bouvet M, Matsubara H, Hoffman RM, Zhao M. Efficacy of tumor-targetingsalmonella typhimuriumA1-R on nude mouse models of metastatic and disseminated human ovarian cancer. J Cell Biochem 2014;115:1996-2003.
109. Zoaby N, Shainsky-Roitman J, Badarneh S, Abumanhal H, Leshansky A, Yaron S, Schroeder A. Autonomous bacterial nanoswimmers target cancer. J Control Release 2017;257:68-75.
110. Toso J. Phase I study of the intravenous administration of attenuated salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol 2002;20:142-52.
111. Zhang Y, Miwa S, Zhang N, Hoffman R, Zhao M. Tumor-targeting Salmonella typhimurium A1-R arrests growth of breast-cancer brain metastasis. Oncotarget 2014;6:2615-22.
112. Alimoradi H, Matikonda SS, Gamble AB, Giles GI, Greish K. Hypoxia responsive drug delivery systems in tumor therapy. Curr Pharm Des 2016;22:2808-20.
113. Loeffler M, Le'Negrate G, Krajewska M, Reed J. Attenuated Salmonella engineered to produce human cytokine LIGHT inhibit tumor growth. Proc Natl Acad Sci U S A 2007;104:12879-83.
114. Loeffler M, Le'Negrate G, Krajewska M, Reed J. IL-18-producing Salmonella inhibit tumor growth. Cancer Gene Ther 2008;15:787-94.
115. Loeffler M, Le'Negrate G, Krajewska M, Reed J. Inhibition of tumor growth using salmonella expressing fas ligand. J Natl Cancer Inst 2008;100:1113-6.
116. Ganai S, Arenas R, Forbes N. Tumour-targeted delivery of TRAIL using Salmonella typhimurium enhances breast cancer survival in mice. Br J Cancer 2009;101:1683-91.
117. Lee CH, Wu C, Shiau A. Endostatin gene therapy delivered bySalmonella choleraesuis in murine tumor models. J Gene Med 2004;6:1382-93.
118. Lee CH, Wu C, Shiau A. Salmonella choleraesuis as an anticancer agent in a syngeneic model of orthotopic hepatocellular carcinoma. Int J Cancer 2008;122:930-5.
119. Zhang L, Gao L, Zhao L, Guo B, Ji K, Tian Y, Wang J, Yu H, Hu J, Kalvakolanu DV, Kopecko DJ, Zhao X, Xu DQ. Intratumoral delivery and suppression of prostate tumor growth by attenuated salmonella enterica serovar typhimurium carrying plasmid-based small interfering RNAs. Cancer Res 2007;67:5859-64.
120. Niethammer AG, Xiang R, Becker J, Wodrich H, Pertl U, Karsten G, Eliceiri BP, Reisfeld RA. A DNA vaccine against VEGF receptor 2 prevents effective angiogenesis and inhibits tumor growth. Nat Med 2002;8:1369-75.
121. Fensterle J, Bergmann B, Yone C, Hotz C, Meyer S, Spreng S, Goebel W, Rapp UR, Gentschevl. Cancer immunotherapy based on recombinant Salmonella enterica serovar Typhimurium aroA strains secreting prostate-specific antigen and cholera toxin subunit B. Cancer Gene Ther 2007;15:85-93.
122. Lemmon MJ, van Zijl P, Fox ME, Mauchline ML, Giaccia AJ, Minton NP, Brown JM. Anaerobic bacteria as a gene delivery system that is controlled by the tumor microenvironment. Gene Ther 1997;4:791-6.
123. Fox ME, Lemmon MJ, Mauchline ML, Davis TO, Giaccia AJ, Minton NP, Brown JM. Anaerobic bacteria as a delivery system for cancer gene therapy: in vitro activation of 5-fluorocytosine by genetically engineered clostridia. Gene Ther 1996;3:173-8.
124. Zhang YL, Lü R, Chang ZS, Zhang WQ, Wang QB, Ding SY, Zhao W. Clostridium sporogenes delivers interleukin-12 to hypoxic tumours, producing antitumour activity without significant toxicity. Lett Appl Microbiol 2014;59:580-6.
125. Groot A, Mengesha A, Wall E, Diest P, Theys J, Vooijs M. Functional antibodies produced by oncolytic clostridia. Biochem Biophys Res Commun 2007;364:985-9.
126. Gunn GR, Zubair A, Peters C, Pan ZK, Wu TC, Paterson Y. Two listeria monocytogenes vaccine vectors that express different molecular forms of human papilloma virus-16 (HPV-16) E7 induce qualitatively different T cell immunity that correlates with their ability to induce regression of established tumors immortalized by HPV-16. J Immunol 2001;167:6471-9.
127. Shahabi V, Seavey M, Maciag P, Rivera S, Wallecha A. Development of a live and highly attenuated Listeria monocytogenes-based vaccine for the treatment of Her2/neu-overexpressing cancers in human. Cancer Gene Ther 2010;18:53-62.
128. Kim S, Castro F, Gonzalez D, Maciag P, Paterson Y, Gravekamp C. Mage-b vaccine delivered by recombinant Listeria monocytogenes is highly effective against breast cancer metastases. B J Cancer 2008;99:741-9.
129. Maciag PC, Seavey MM, Pan ZK, Ferrone S, Paterson Y. Cancer immunotherapy targeting the high molecular weight melanoma-associated antigen protein results in a broad antitumor response and reduction of pericytes in the tumor vasculature. Cancer Res 2008;68:8066-75.
130. Zu C, Wang J. Tumor-colonizing bacteria: a potential tumor targeting therapy. Crit Rev Microbiol 2013;40:225-35.
131. Quispe-Tintaya W, Chandra D, Jahangir A, Harris M, Casadevall A, Dadachova E, Gravekamp C. Nontoxic radioactive Listeriaat is a highly effective therapy against metastatic pancreatic cancer. Proc Natl Acad Sci U S A 2013;110:8668-73.
132. Hosseinidoust Z, Mostaghaci B, Yasa O, Park B, Singh A, Sitti M. Bioengineered and biohybrid bacteria-based systems for drug delivery. Adv Drug Deliv Rev 2016;106:27-44.
133. Fu W, Chu L, Han X, Liu X, Ren D. Synergistic antitumoral effects of human telomerase reverse transcriptase-mediated dual-apoptosis-related gene vector delivered by orally attenuated Salmonella enterica Serovar Typhimurium in murine tumor models. J Gene Med 2008;10:690-701.
134. Cicchelero L, Denies S, Devriendt B, de Rooster H, Sanders N. Can dendritic cells improve whole cancer cell vaccines based on immunogenically killed cancer cells? Onco Immunology 2015;4:e1048413.
135. Lin IY, Van TT, Smooker PM. Live-attenuated bacterial vectors: tools for vaccine and therapeutic agent delivery. Vaccines (Basel) 2015;3:940-72.
136. Inoue H, Tani K. Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments. Cell Death Differ 2013;21:39-49.
137. Tsuchiya K, Hara H, Fang R, Hernandez-Cuellar E, Sakai S, Daim S, Chen X, Dewamitta SR, Qu H, Mitsuyama M, Kawamura I. The adaptor ASC exacerbates lethal Listeria monocytogenes infection by mediating IL-18 production in an inflammasome-dependent and -independent manner. Eur J Immunol 2014;44:3696-707.
138. Srivastava S, Pelloso D, Feng H, Voiles L, Lewis D, Haskova Z, Whitacre M, Trulli S, Chen YJ, Toso J, Jonak ZL, Chang HC, Robertson MJ. Effects of interleukin-18 on natural killer cells: costimulation of activation through Fc receptors for immunoglobulin. Cancer Immunol Immunother 2013;62:1073-82.
139. Cao H, Xiang T, Zhang C, Yang H, Jiang L, Liu S, Huang X. MDA7 combined with targeted attenuated Salmonella vector SL7207/pBud-VP3 inhibited growth of gastric cancer cells. Biomed Pharmacother 2016;83:809-15.
140. Farooqi A, De Rosa G. TRAIL and microRNAs in the treatment of prostate cancer: therapeutic potential and role of nanotechnology. Appl Microbiol Biotechnol 2013;97:8849-57.
141. Zheng X, Ou Y, Shu M, Wang Y, Zhou Y, Su X, Zhu W, Yin W, Li S, Qiu P, Yan G, Zhang J, Hu J, Xu D. Cholera toxin, a typical protein kinase A activator, induces G1 phase growth arrest in human bladder transitional cell carcinoma cells via inhibiting the c-Raf/MEK/ERK signaling pathway. Mol Med Rep 2014;9:1773-9.
142. Zhao Q, Qu X, Liu K, Shi H, Yang G, Zhou B, Zhu L, Zhang W, Yan Z, Liu R, Qian S, Wang J. Microwave ablation combined with attenuated Salmonella typhimurium for treating hepatocellular carcinoma in a rat model. Oncotarget 2017;8:47655-64.
143. Morgan RA, Chinnasamy N, Abate-Daga D, Gros A, Robbins PF, Zheng Z, Dudley ME, Feldman SA, Yang JC, Sherry RM, Phan GQ, Hughes MS, Kammula US, Miller AD, Hessman CJ, Stewart AA, Restifo NP, Quezado MM, Alimchandani M, Rosenberg AZ, Nath A, Wang T, Bielekova B, Wuest SC, Akula N, McMahon FJ, Wilde S, Mosetter B, Schendel DJ, Laurencot CM, Rosenberg SA. .
144. Jiang SN, Phan TX, Nam TK, Nguyen VH, Kim HS, Bom HS, Choy HE, Hong Y, Min JJ. Inhibition of tumor growth and metastasis by a combination of Escherichia coli-mediated cytolytic therapy and radiotherapy. Mol Ther 2010;18:635-42.
145. Keates AC, Fruehauf J, Xiang S, Li CJ. TransKingdom RNA interference: a bacterial approach to challenges in RNAi therapy and delivery. Biotechnol Genet Eng Rev 2008;25:113-28.
146. Yang N, Li SH, Lü YZ, Chen LS, Ren DM. Attenuated Salmonella typhimurium carrying shRNA-expressing vectors elicit RNA interference in murine bladder tumors. Acta Pharmacol Sin 2011;32:368-74.
147. Tian Y, Guo B, Jia H, Ji K, Sun Y, Li Y, Zhao T, Gao L, Meng Y, Kalvakolanu DV, Kopecko DJ, Zhao X, Zhang L, Xu D. Targeted therapy via oral administration of attenuated Salmonella expression plasmid-vectored Stat3-shRNA cures orthotopically transplanted mouse HCC. Cancer Gene Ther 2012;19:393-401.
148. Yu YA, Weibel S, Szalay AA. Real-time imaging of tumors using replication-competent light-emitting microorganisms. Methods Mol Biol 2012;872:159-75.
149. Brader P, Stritzker J, Riedl CC, Zanzonico P, Cai S, Burnazi EM, Ghani ER, Hricak H, Szalay AA, Fong Y, Blasberg R. Escherichia coli Nissle 1917 facilitates tumor detection by positron emission tomography and optical imaging. Clin Cancer Res 2008;14:2295-302.
150. Viczián A, Kircher S. Luciferase and green fluorescent protein reporter genes as tools to determine protein abundance and intracellular dynamics. Methods Mol Biol 2010;655:293-312.
151. Voisey CR, Marincs F. Elimination of internal restriction enzyme sites from a bacterial luminescence (luxCDABE) operon. Biotechniques 1998;24:56-8.
152. Sörensen M, Lippuner C, Kaiser T, Misslitz A, Aebischer T, Bumann D. Rapidly maturing red fluorescent protein variants with strongly enhanced brightness in bacteria. FEBS Lett 2003;552:110-4.
153. Yu YA, Zhang Q, Szalay AA. Establishment and characterization of conditions required for tumor colonization by intravenously delivered bacteria. Biotechnol Bioeng 2008;100:567-78.
154. Araujo AC, Abreu F, Silva KT, Bazylinski DA, Lins U. Magnetotactic bacteria as potential sources of bioproducts. Mar Drugs 2015;13:389-430.
155. Nakamura C, Burgess JG, Sode K, Matsunaga T. An iron-regulated gene, magA, encoding an iron transport protein of magnetospirillum sp. strain AMB-1. J Biol Chem 1995;270:28392-6.
156. Mannucci S, Ghin L, Conti G, Tambalo S, Lascialfari A, Orlando T, Benati D, Bernardi P, Betterle N, Bassi R, Marzola P, Sbarbati A. Magnetic nanoparticles from magnetospirillum gryphiswaldense increase the efficacy of thermotherapy in a model of colon carcinoma. PLoS One 2014;9:e108959.
157. Want CZ, Kazmierczak RA, Eisenstark A. Straings, mechanism and perspective; Salmonella-based cancer therapy. Int J Microbiol 2016;2016:5678702.
158. Danino T, Prindle A, Kwong G, Skalak M, Li H, Allen K, Hasty J, Bhatia SN. Programmable probiotics for detection of cancer in urine. Sci Transl Med 2015;7:289ra84.
159. Mangtani P, Abubakar I, Ariti C, Beynon R, Pimpin L, Fine PE, Rodrigues LC, Smith PG, Lipman M, Whiting PF, Sterne JA. Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials. Clin Infect Dis 2013;58:470-80.
160. Kassouf W, Traboulsi SL, Kulkarni GS, Breau RH, Zlotta A, Fairey A, So A, Lacombe L, Rendon R, Aprikian AG, Siemens DR, Izawa JI, Black P. CUA guidelines on the management of non-muscle invasive bladder cancer. Can Urol Assoc J 2015;9:690.
161. Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DW, Kurth K. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using eortc risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol 2006;49:466-77.
162. Sylvester RJ, Brausi MA, Kirkels WJ, Hoeltl W, Calais Da Silva F, Powell PH, Prescott S, Kirkali Z, van de Beek C, Gorlia T, de Reijke TM; EORTC Genito-Urinary Tract Cancer Group. Long-term efficacy results of eortc genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus calmette-guérin, and bacillus calmette-guérin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder. Eur Urol 2010;57:766-73.
163. Babjuk M, Burger M, Zigeuner R, Shariat S, van Rhijn BW, Compérat E, Sylvester RJ, Kaasinen E, Böhle A, Palou Redorta J, Rouprêt M; European Association of Urology. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2013. Eur Urol 2013;64:639-53.
164. Brausi M, Oddens J, Sylvester R, Bono A, van de Beek C, van Andel G, Gontero P, Turkeri L, Marreaud S, Collette S, Oosterlinck W. Side Effects of Bacillus Calmette-Guérin (BCG) in the treatment of intermediate- and high-risk Ta, T1 papillary carcinoma of the bladder: results of the EORTC genito-urinary cancers group randomised phase 3 study comparing one-third dose with full dose and 1 year with 3 years of maintenance BCG. Eur Urol 2014;65:69-76.
165. Redelman-Sidi G, Glickman M, Bochner B. The mechanism of action of BCG therapy for bladder cancer-a current perspective. Nat Rev Urol 2014;11:153-62.
166. Kawai K, Miyazaki J, Joraku A, Nishiyama H, Akaza H. Bacillus Calmette-Guerin (BCG) immunotherapy for bladder cancer: current understanding and perspectives on engineered BCG vaccine. Cancer Sci 2013;104:22-7.
167. Pandith AA, Khan NP, Azad NA, Khan MS, Wani MS. Association of chemokine and chemokine receptor gene polymorphis (MCP1 A-2518G and CCR2-V64I) with urinary bladder cancer: a study in kashmiri population. Am J Mol Cell Biol 2013;2:1-13.
168. Fuge O, Vasdev N, Allchorne P, Green JS. Immunotherapy for bladder cancer. Res Rep Urol 2015;7:65-79.
169. Bunimovich-Mendrazitsky S, Halachmi S, Kronik N. Improving Bacillus Calmette-Guérin (BCG) immunotherapy for bladder cancer by adding interleukin 2 (IL-2): a mathematical model. Math Med Biol 2016;33:159-88.
170. Iqbal NT, Hussain R. Non-specific immunity of BCG vaccine: a perspective of BCG immunotherapy. Trials Vaccinol 2014;3:143-9.
171. Kates M, Nirschl T, Sopko NA, Matsui H, Kochel CM, Reis LO, Netto GJ, Hoque MO, Hahn NM, McConkey DJ, Baras AS, Drake CG, Bivalacqua TJ. Intravesical BCG Induces CD4 + T-cell expansion in an immune competent model of bladder cancer. Cancer Immunol Res 2017;5:594-603.
172. Gandhi NM, Morales A, Lamm DL. Bacillus Calmette-Guérin immunotherapy for genitourinary cancer. BJU Int 2013;112:288-97.
173. Amarante-Mendes GP, Griffith TS. Therapeutic applications of TRAIL receptor agonists in cancer and beyond. Pharmacol Ther 2015;155:117-31.
174. Liu X, Dowell AC, Patel P, Viney RP, Foster MC, Porfiri E, James ND, Bryan RT. Cytokines as effectors and predictors of responses in the treatment of bladder cancer by bacillus Calmette-Guérin. Future Oncol 2014;10:1443-56.
175. Nemunaitis J, Cunningham C, Senzer N, Kuhn J, Cramm J, Litz C, Cavagnolo R, Cahill A, Clairmont C, Sznol M. Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients. Cancer Gene Ther 2003;10:737-44.
176. Schmitz-Winnenthal FH, Hohmann N, Niethammer A, Friedrich T, Lubenau H, Springer M, Breiner KM, Mikus G, Weitz J, Ulrich A, Buechler MW, Pianka F, Klaiber U, Diener M, Leowardi C, Schimmack S, Sisic L, Keller AV, Koc R, Springfeld C, Knebel P, Schmidt T, Ge Y, Bucur M, Stamova S, Podola L, Haefeli WE, Grenacher L, Beckhove P. Anti-angiogenic activity of VXM01, an oral T-cell vaccine against VEGF receptor 2, in patients with advanced pancreatic cancer: A randomized, placebo-controlled, phase 1 trial. Onco Immunol 2015;4:e1001217.
177. Le DT, Brockstedt D, Nir-Paz RG, Hampl J, Mathur S, Nemunaitis J, Sterman DH, Hassan R, Lutz E, Moyer B, Giedlin M, Louis JL, Sugar EA, Pons A, Cox AL, Levine J, Murphy AL, Illei P, Dubensky TW Jr, Eiden JE, Jaffee EM, Laheru DA. A live-attenuated listeria vaccine (ANZ-100) and a live-attenuated listeria vaccine expressing mesothelin (CRS-207) for advanced cancers: phase I studies of safety and immune induction. Clin Cancer Res 2011;18:858-68.
178. Le DT, Wang-Gillam A, Picozzi V, Greten TF, Crocenzi T, Springett G, Morse M, Zeh H, Cohen D, Fine RL, Onners B, Uram JN, Laheru DA, Lutz ER, Solt S, Murphy AL, Skoble J, Lemmens E, Grous J, Dubensky T Jr, Brockstedt DG, Jaffee EM. Safety and survival with GVAX pancreas prime and listeria monocytogenes-expressing mesothelin (CRS-207) boost vaccines for metastatic pancreatic cancer. J Clin Oncol 2015;33:1325-33.
179. Pollheimer M, Kornprat P, Lindtner R, Harbaum L, Schlemmer A, Rehak P, Langner C. Tumor necrosis is a new promising prognostic factor in colorectal cancer. Hum Pathol 2010;41:1749-57.
180. Ladstein RG, Bachmann IM, Straume O, Akslen LA. Tumor necrosis is a prognostic factor in thick cutaneous melanoma. Am J Surg Pathol 2012;36:1477-82.
181. Swinson D, Jones J, Richardson D, Cox G, Edwards J, O'Byrne K. Tumour necrosis is an independent prognostic marker in non-small cell lung cancer: correlation with biological variables. Lung Cancer 2002;37:235-40.
182. Staedtke V, Bai RY, Sun W, Huang J, Kibler KK, Tyler BM, Gallia GL, Kinzler K, Vogelstein B, Zhou S, Riggins GJ. Clostridium novyi-NT can cause regression of orthotopically implanted glioblastomas in rats. Oncotarget 2015;6:5536-46.
183. Krick EL, Sorenmo KU, Rankin SC, Cheong I, Kobrin B, Thornton K, Kinzler KW, Vogelstein B, Zhou S, Diaz LA Jr. Evaluation of Clostridium novyi -NT spores in dogs with naturally occurring tumors. Am J Vet Res 2012;73:112-8.
184. Kubiak A, Minton N. The potential of clostridial spores as therapeutic delivery vehicles in tumour therapy. Res Microbiol 2015;166:244-54.
185. Maciag P, Radulovic S, Rothman J. The first clinical use of a live-attenuated Listeria monocytogenes vaccine: a phase I safety study of Lm-LLO-E7 in patients with advanced carcinoma of the cervix. Vaccine 2009;27:3975-83.
186. Theys J, Pennington O, Dubois L, Anlezark G, Vaughan T, Mengesha A, Landuyt W, Anné J, Burke PJ, Dûrre P, Wouters BG, Minton NP, Lambin P. Repeated cycles of Clostridium-directed enzyme prodrug therapy result in sustained antitumour effects in vivo. Br J Cancer 2006;95:1212-9.
187. Fabricius EM, Schneeweiss U, Schau HP, Schmidt W, Benedix A. Quantitative investigations into the elimination of in vitro-obtained spores of the non-pathogenic Clostridium butyricum strain CNRZ 528, and their persistence in organs of different species following intravenous spore administration. Res Microbiol 1993;144:741-53.
188. Nuyts S, Van Mellaert L, Theys J, Landuyt W, Bosmans E, Anné J, Lambin P. Radio-responsive recA promoter significantly increases TNFα production in recombinant clostridia after 2 Gy irradiation. Gene Ther 2001;8:1197-1201.
189. Barbé S, Mellaert L, Theys J, Geukens N, Lammertyn E, Lambin P, Anné J. Secretory production of biologically active rat interleukin-2 by Clostridium acetobutylicum DSM792 as a tool for anti-tumor treatment. FEMS Microbiol Lett 2005;246:67-73.
190. Bermudes D, Low K, Ittensohn M, Le T, Platt J, Sodi S, Amoss M, Ash O, Carmichael E, Chakraborty A, Fischer J, Lin SL, Luo X, Miller SI, Zheng L, King I, Pawelek JM, Bermudes D. Lipid a mutant Salmonella with suppressed virulence and TNFalpha induction retain tumor-targeting in vivo. Nat Biotechnol 1999;17:37-41.
191. Clairmont C, Lee KC, Pike J, Ittensohn M, Low KB, Pawelek J, Bermudes D, Brecher SM, Margitich D, Turnier J, Li Z, Luo X, King I, Zheng LM. Biodistribution and genetic stability of the novel antitumor agent VNP20009, a genetically modified strain of Salmonella typhimurium. J Infect Dis 2000;181:1996-2002.
193. Aghi M, Hochberg F, Breakefield X. Prodrug activation enzymes in cancer gene therapy. J Gene Med 2000;2:148-64.
194. Nagakura C, Hayashi K, Zhao M, Yamauchi K, Yamamoto N, Tsuchiya H, Tomita K, Bouvet M, Hoffman RM. Efficacy of a genetically-modified Salmonella typhimurium in an orthotopic human pancreatic cancer in nude mice. Anticancer Res 2009;29:1873-8.
195. Hiroshima Y, Zhao M, Zhang Y, Maawy A, Hassanein M, Uehara F, Miwa S, Yano S, Momiyama M, Suetsugu A, Chishima T, Tanaka K, Bouvet M, Endo I, Hoffman RM. Comparison of efficacy of Salmonella typhimuriumA1-R and chemotherapy on stem-like and non-stem human pancreatic cancer cells. Cell Cycle 2013;12:2774-80.
196. Momiyama M, Zhao M, Kimura H, Tran B, Chishima T, Bouvet M, Endo I, Hoffman RM. Inhibition and eradication of human glioma with tumor-targetingSalmonella typhimuriumin an orthotopic nude-mouse model. Cell Cycle 2012;11:628-32.
197. Murakami T, Hiroshima Y, Zhao M, Zhang Y, Chishima T, Tanaka K, Bouvet M, Endo I, Hoffman RM. Therapeutic efficacy of tumor-targeting Salmonella typhimurium A1-R on human colorectal cancer liver metastasis in orthotopic nude-mouse models. Oncotarget 2015;6:31368-77.
198. Matsumoto Y, Miwa S, Zhang Y, Hiroshima Y, Yano S, Uehara F, Yamamoto M, Toneri M, Bouvet M, Matsubara H, Hoffman RM, Zhao M. Efficacy of tumor-targeting Salmonella typhimurium A1-R on nude mouse models of metastatic and disseminated human ovarian cancer. J Cell Biochem 2014;115:1996-2003.
199. Zhang Y, Zhang N, Zhao M, Hoffman RM. Comparison of the selective targeting efficacy of Salmonella typhimurium A1-R and VNP20009 on the Lewis lung carcinoma in nude mice. Oncotarget 2015;6:14625-31.
200. Yano S, Zhang Y, Miwa S, Tome Y, Hiroshima Y, Uehara F, Yamamoto M, Suetsugu A, Kishimoto H, Tazawa H, Zhao M, Bouvet M, Fujiwara T, Hoffman RM. Spatial-temporal FUCCI imaging of each cell in a tumor demonstrates locational dependence of cell cycle dynamics and chemoresponsiveness. Cell Cycle 2014;13:2110-9.
201. Yano S, Zhang Y, Zhao M, Hiroshima Y, Miwa S, Uehara F, Kishimoto H, Tazawa H, Bouvet M, Fujiwara T, Hoffman RM. Tumor-targeting Salmonella typhimurium A1-R decoys quiescent cancer cells to cycles as visualized by FUCCI imaging and become sensitive to chemotherapy. Cell Cycle 2014;13:2958-3963.
202. Jia H, Li Y, Zhao T, Li X, Hu J, Yin D, Guo B, Kopecko DJ, Zhao X, Zhang L, Xu DQ. Antitumor effects of Stat3-siRNA and endostatin combined therapies, delivered by attenuated Salmonella, on orthotopically implanted hepatocarcinoma. Cancer Immunol Immunother 2012;61:1977-87.
203. Park SY, Groisman EA. Signal-specific temporal response by the SalmonellaPhoP/PhoQ regulatory system. Mol Microbiol 2013;91:135-44.
204. Hohmann EL, Oletta CA, Killeen KP, Miller SI. PhoP/PhoQ-deleted Salmonella typhi (Ty800) is a safe and immunogenic single dose typhoid fever vaccine in volunteers. J Infect Dis 1996;173:1408-14.
205. Yu H, Pardoll D, Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat Rev Cancer 2009;9:798-809.
206. Nam S, Buettner R, Turkson J, Kim D, Cheng JQ, Muehlbeyer S, Hippe F, Vatter S, Merz KH, Eisenbrand G, Jove R. Indirubin derivatives inhibit Stat3 signaling and induce apoptosis in human cancer cells. Proc Natl Acad Sci U S A 2005;102:5998-6003.
208. Chen Y, Liu X, Jin C, Zhou YC, Navab R, Jakobsen KR, Chen XQ, Li J, Li TT, Luo L, Wang XC. An orally administered DNA vaccine targeting vascular endothelial growth factor receptor-3 inhibits lung carcinoma growth. Tumour Biol 2015;37:2395-404.
209. Xu X, Hegazy WA, Guo L, Gao X, Courtney AN, Kurbanov S, Liu D, Tian G, Manuel ER, Diamond DJ, Hensel M, Metelitsa LS. Effective cancer vaccine platform based on attenuated Salmonella and a Type III secretion system. Cancer Res 2014;74:6260-70.
210. Weiskirch LM, Pan ZK, Paterson Y. The tumor recall response of antitumor immunity primed by a live, recombinant listeria monocytogenes vaccine comprises multiple effector mechanisms. Clin Immunol 2001;98:346-57.
211. Jahangir A, Chandra D, Quispe-Tintaya W, Singh M, Selvanesan BC, Gravekamp C. Immunotherapy with Listeria reduces metastatic breast cancer in young and old mice through different mechanisms. Onco Immunology 2017;6:e1342025.
212. Wallecha A, Singh R, Malinina I. Listeria monocytogenes (Lm)-LLO Immunotherapies reduce the immunosuppressive activity of myeloid-derived suppressor cells and regulatory T cells in the tumor microenvironment. J Immunother 2013;36:468-76.
213. Pan Z, Ikonomidis G, Pardoll D, Paterson Y. Regression of established tumors in mice mediated by the oral administration of a recombinant Listeria monocytogenes vaccine. Cancer Res 1995;55:4776-9.
214. Wallecha A, Carroll KD, Maciag PC, Rivera S, Shahabi V, Paterson Y. Multiple effector mechanisms induced by recombinant Listeria monocytogenes anticancer immunotherapeutics. Adv Appl Microbiol 2009;66:1-27.
215. Birmingham CL, Canadien V, Kaniuk NA, Steinberg BE, Higgins DE, Brumell JH. Listeriolysin O allows Listeria monocytogenes replication in macrophage vacuoles. Nature 2008;451:350-4.
216. Schnupf P, Zhou J, Varshavsky A, Portnoy DA. Listeriolysin O secreted by Listeria monocytogenes into the host cell cytosol is degraded by the N-end rule pathway. Infect Immun 2007;75:5135-47.
217. Eitel J, Suttorp N, Opitz B. Innate immune recognition and inflammasome activation in Listeria monocytogenes infection. Front Microbiol 2011;1:149.
218. Weiskirch L, Paterson Y. Listeria monocytogenes: a potent vaccine vector for neoplastic and infectious disease. Immunol Rev 1997;158:159-69.
219. Ikonomidis G, Paterson Y, Kos FJ, Portnoy DA. Delivery of a viral antigen to the class I processing and presentation pathway by Listeria monocytogenes. J Exp Med 1994;180:2209-18.
220. Mata M, Yao ZJ, Zubair A, Syres K, Paterson Y. Evaluation of a recombinant Listeria monocytogenes expressing an HIV protein that protects mice against viral challenge. Vaccine 2001;19:1435-45.
221. Singh R, Wallecha A. Cancer immunotherapy using recombinant Listeria monocytogenes: transition from bench to clinic. Hum Vaccin 2011;7:497-505.
222. Tilney LG, Portnoy DA. Actin filaments and the growth, movement, and spread of the intracellular bacterial parasite, Listeria monocytogenes. J Cell Biol 1989;109:1597-608.
223. Theisen E, Sauer JD. Listeria monocytogenesand the inflammasome: from cytosolic bacteriolysis to tumorimmunotherapy. Curr Top Microbiol Immunol 2016;397:133-60.
224. Cory L, Chu C. ADXS-HPV: a therapeutic Listeria vaccination targeting cervical cancers expressing the HPV E7 antigen. Hum Vaccin Immunother 2014;10:3190-5.
225. Shahabi V, Reyes-Reyes M, Wallecha A, Rivera S, Paterson Y, Maciag P. Development of a Listeria monocytogenes based vaccine against prostate cancer. Cancer Immunol Immunother 2008;57:1301-3.
226. Chen Y, Yang D, Li S, Gao Y, Jiang R, Deng L, Frankel FR, Sun B. Development of a Listeria monocytogenes-based vaccine against hepatocellular carcinoma. Oncogene 2011;31:2140-52.
227. Keenan B, Saenger Y, Kafrouni M, Leubner A, Lauer P, Maitra A, Rucki AA, Gunderson AJ, Coussens LM, Brockstedt DG, Dubensky TW Jr, Hassan R, Armstrong TD, Jaffee EM. A Listeria vaccine and depletion of T-regulatory cells activate immunity against early stage pancreatic intraepithelial neoplasms and prolong survival of mice. Gastroenterology 2014;146:1784-94.
228. Wood L, Paterson Y. Attenuated Listeria monocytogenes: a powerful and versatile vector for the future of tumor immunotherapy. Front Cell Infect Microbiol 2014;4:51.
229. Brockstedt D, Bahjat K, Giedlin M, Liu W, Leong M, Luckett W, Luckett W, Gao Y, Schnupf P, Kapadia D, Castro G, Lim JY, Sampson-Johannes A, Herskovits AA, Stassinopoulos A, Bouwer HG, Hearst JE, Portnoy DA, Cook DN, Dubensky TW Jr. Killed but metabolically active microbes: a new vaccine paradigm for eliciting effector T-cell responses and protective immunity. Nat Med 2005;11:853-60.
230. Li Z, Zhao X, Higgins DE, Frankel FR. Conditional lethality yields a new vaccine strain of Listeria monocytogenes for the induction of cell-mediated immunity. Infect Immun 2005;73:5065-73.
231. Lauer P, Chow M, Loessner M, Portnoy D, Calendar R. Construction, characterization, and use of two Listeria monocytogenes site-specific phage integration vectors. J Bacteriol 2002;184:4177-86.
232. Angelakopoulos H, Loock K, Sisul DM, Jensen ER, Miller JF, Hohmann EL. Safety and shedding of an attenuated strain of Listeria monocytogenes with a deletion of actA/plcB in adult volunteers: a dose escalation study of oral inoculation. Infect Immun 2002;70:3592-3601.
233. Verch T, Pan ZK, Paterson Y. Listeria monocytogenes-based antibiotic resistance gene-free antigen delivery system applicable to other bacterial vectors and DNA vaccines. Infect Immun 2004;72:6418-25.
234. Sacco JJ, Evans M, Harrington KJ, Man S, Powell N, Shaw RJ, Jones TM. Systemic listeriosis following vaccination with the attenuated Listeria monocytogenestherapeutic vaccine, ADXS11-001. Hum Vaccin Immunother 2015;12:1085-6.
235. Correction: mesothelin-specific chimeric antigen receptor mRNA-engineered T cells induce antitumor activity in solid malignancies. .
236. Hassan R, Laszik ZG, Lerner M, Raffeld M, Postier R, Brackett D. Mesothelin is overexpressed in pancreaticobiliary adenocarcinomas but not in normal pancreas and chronic pancreatitis. Am J Clin Pathol 2005;124:838-45.
237. He X, Wang L, Riedel H, Wang K, Yang Y, Dinu CZ, Rojanasakul Y. Mesothelin promotes epithelial-to-mesenchymal transition and tumorigenicity of human lung cancer and mesothelioma cells. Mol Cancer 2017;16:63.
238. Mkrtichyan M, Chong N, Abu Eid R, Wallecha A, Singh R, Rothman J, Khleif SN. Anti-PD-1 antibody significantly increases therapeutic efficacy of Listeria monocytogenes (Lm)-LLO immunotherapy. J Immunother Cancer 2013;1:15.
239. Han KJ, Lee NK, Park H, Paik HD. Anticancer and anti-inflammatory activity of probiotic lactococcus lactis NK34. J Microbiol Biotechnol 2015;25:1697-701.
240. Kim JY, Woo HJ, Kim YS, Kim KH, Lee HJ. Cell cycle dysregulation induced by cytoplasm of lactococcus lactis ssp. lactis in SNUC2A, a colon cancer cell line. Nutr Cancer 2003;46:197-201.
241. Kim SY, Kim JE, Lee KW, Lee HJ. Lactococcus lactis ssp. lactis inhibits the proliferation of SNU-1 human stomach cancer cells through induction of G0/G1 cell cycle arrest and apoptosis via p53 and p21 expression. Ann N Y Acad Sci 2009;1171:270-5.
242. Maletzki C, Linnebacher M, Kreikemeyer B, Emmrich J. Pancreatic cancer regression by intratumoral injection of live Streptococcus pyogenes in a syngeneic mouse model. Gut 2008;57:483-91.
243. Yin X, Yu B, Tang Z, He B, Ren J, Xiao X, Tang W. Bifidobacterium infantis-mediated HSV-TK/GCV suicide gene therapy induces both extrinsic and intrinsic apoptosis in a rat model of bladder cancer. Cancer Gene Ther 2012;20:77-81.
244. Bhatnagar PK, Awasthi A, Nomellini JF, Smit J, Suresh MR. Anti-tumor effects of the bacterium caulobacter crescentus in murine tumor models. Cancer Biol Ther 2006;5:485-91.
